ArticleBiotechnology journal2026
Mycoponics: Controlled Bioproduction Utilizing Biophysical, Solid-State, Liquid Nutrient Delivery.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mycoponics: Controlled Bioproduction Utilizing Biophysical, Solid-State, Liquid Nutrient Delivery.Biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mycoponic biotechnology, inspired by hydroponics-a vital technology for agriculture research and space exploration, is limited by innate substrate contamination commonplace in commercial mycoproduction. Using micro-structured ceramic tubes as "substrate," mycoponics provides mycelial cellular filaments with an air-phase/solid-state, antimicrobial interface for cellular liquid nutrient media uptake. We show how antimicrobial biophysical size exclusion facilitates mycoponic "persistent-filtration-defense" (PFD), experimentally confirmed using flow cytometry, and electron microscopic analysis of the interfacial ceramic pores (less than 300 nm). The antimicrobial mycoponic interface enabled development of a complete mycoponic nutrient medium, producing blue oyster mushrooms from liquid culture 2 weeks post inoculation. This completely eliminates grain-spawn (2-4 weeks) and fruiting phase (2-4 weeks) times using granular substrate bags that require energy/time-intensive antimicrobial processing. Mycelial colonization times decreased by 9 days, while biomass increased (170%) with activated carbon inside the tubes. Mycoponic cultivation of Reishi mycoleather gloves demonstrates direct 3D-mycomaterials, and we show how mycoponics enables advanced scientific imaging (thermal) and techniques, including mycelial exudate recovery for drug discovery. Mycoponics enables hybrid solid-state, liquid culture for continuous bioproduction of mycelial pharmaceuticals, representing 18% of the global market. The efficiency and extended cultivation enabled by mycoponics will facilitate significant future advances in mycology and mycoengineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.